Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Oral GLP-1 weight loss medication Orfoglipron (Eli Lilly) is nearing an FDA decision with available expect mid-2026 Clinical trials show meaningful results: 12-16% 1,2 average weight loss, which is slightly less than injectables Side effects are similar: mostly gastrointestinal, such as nausea or diarrhea, typically improving over 23 months
Bowker N, Hansford R, Burgess S, Foley CN, Auyeung VPW, Erzurumluoglu AM, Stewart ID, Wheeler E, Pietzner M, Gribble F, et al
Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article
When the pharmacy, provider, and platform are all vertically integrated, whos accountable
As with women's health considerations, these questions require individualized clinical evaluation by the prescribing provider
Heres what that minority does differently
US$ 29.41
US$ 25.69
US$ 26.64
US$ 27.52
US$ 21.75
US$ 29.61
US$ 21.13
US$ 26.74
